Research
Psychedelic-Assisted Therapy (Pat): A New Frontier in Mental Health Treatment
The journal of desk research review and analysis. – December 16, 2025
Summary
Psychedelic-assisted therapy (PAT) shows remarkable potential in treating mental health disorders, with studies indicating a 60-70% reduction in depression symptoms among participants. Recent clinical trials from 2020 to 2024 involved diverse sample sizes, revealing significant benefits for conditions like PTSD and substance use disorders. Emerging evidence emphasizes the importance of addressing ethical issues and exploring underrepresented groups, such as older adults. This synthesis highlights the need for continued investigation into PAT's mechanisms and regulatory frameworks, paving the way for future advancements in psychiatry and psychology.
Abstract
Psychedelic-assisted therapy (PAT) has emerged as a promising and innovative approach to treating a range of mental health disorders, including dep...
Lysergic acid diethylamide-derived excitatory/inhibitory ratio change enhances global synchrony in functional brain dynamics
PLoS Computational Biology – December 15, 2025
Summary
LSD significantly enhances global brain synchrony and dynamic complexity, leading to a unique brain state that blurs the lines between perception and cognition. In a study analyzing resting-state fMRI data from 30 participants, LSD was shown to stabilize a globally synchronized, non-modular brain state, increasing transitions within cognitive control networks. This phenomenon is linked to a convergence in excitatory/inhibitory balance across cortical areas, suggesting that LSD may facilitate cognitive flexibility and potentially hold therapeutic promise for mental disorders marked by rigid thought patterns.
Abstract
Lysergic acid diethylamide (LSD) has shown remarkable potential in modulating brain functional organization and dynamics. However, the exact mechan...
The Effects of Educational Materials on Knowledge and Attitudes Toward Psilocybin
OpenAlex – December 15, 2025
Summary
Psilocybin-assisted therapy (PAT) offers hope for the nearly 50% of individuals with major depressive disorder who do not respond to traditional antidepressants. A study involving 150 participants explored whether a brief educational intervention could enhance public understanding of PAT. While no significant changes in knowledge or attitudes were observed, the sample predominantly comprised white, college-educated adults, many of whom had prior psychedelic experience. This demographic limitation suggests that broader outreach is essential for improving perceptions of this innovative mental health treatment.
Abstract
Depression is one of the most prevalent and burdensome mental health conditions worldwide, affecting millions and contributing to over 700,000 deat...
Psilocybin-assisted psychotherapy for treatment-resistant obsessive–compulsive disorder: protocol for an open-label pilot study
BJPsych Open – December 15, 2025
Summary
Up to 60% of individuals with Obsessive-Compulsive Disorder (OCD) don't improve with standard therapies. A 12-week trial is exploring psilocybin-assisted psychotherapy for these treatment-resistant cases. Ten adults will receive a single 25 mg dose of psilocybin alongside psychological support. This initiative will assess the intervention's safety, tolerability, and preliminary clinical effects, using tools like the Yale–Brown Obsessive–Compulsive Scale. Additionally, it will examine brain changes to understand how psilocybin might work. These preliminary findings will guide larger studies into this promising approach for severe OCD.
Abstract
Background Obsessive–compulsive disorder (OCD) is a debilitating mental disorder commonly treated with selective serotonin reuptake inhibitors, aty...
Esketamine/Ketamine: Dual‐Action Mechanisms and Clinical Prospects beyond Anesthesia in Psychiatry, Immunology, and Oncology
Advanced Science – December 14, 2025
Summary
Esketamine and ketamine are gaining traction as effective perioperative analgesics and anesthetics, with their applications in the U.S. and Europe already established. In China, however, their use is still emerging. These drugs primarily work by blocking the N-methyl-D-aspartate receptor, offering benefits like pain relief and potential antidepressant effects. Despite their promise, concerns about side effects and addiction have led to regulatory restrictions. Comprehensive analysis of clinical and preclinical studies highlights their versatile roles in anesthesia, cancer treatment, and immune response management.
Abstract
Esketamine and ketamine are perioperative analgesics and anesthetics that have been widely adopted in clinical practice in Europe and the United St...
ALADIN ∞ ℂ(t) — The Final Law of the Universe: Complete Repository (December 2025) — 430 MB Definitive Archive
Zenodo (CERN European Organization for Nuclear Research) – December 14, 2025
Summary
A groundbreaking finding reveals that a primordial current density of 1.000 × 10¹⁸ A/m² can explain cosmology, consciousness, and quantum biology without invoking dark matter or energy. This comprehensive archive includes 486 reproducible Python proofs and raw EEG data from breakthrough subjects undergoing experiences like 5-MeO-DMT and sustained meditation. Key insights include consciousness as a physical field oscillating at 43 Hz, ego dissolution at 41 seconds, and a measurable immortality switch, suggesting profound connections between neurophysiology and enlightenment.
Abstract
Mihai Alexandru Bucurenciu (Aladin), independent researcher, Sibiu, Romania. This is the complete and definitive archive of ALADIN ∞ ℂ(t) — the Fin...
Supplementary material for: Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study
Zenodo (CERN European Organization for Nuclear Research) – December 13, 2025
Summary
A compelling neuroscience finding reveals that the spatial organization of the cingulate cortex strongly predicts psilocybin's effects on consciousness. In 25 healthy participants, magnetic resonance imaging revealed an anterior-posterior gradient in cingulate cortex thickness, which showed a robust association (r = 0.676) with the intensity of altered states of consciousness induced by psilocybin (0.26 mg/kg). While a prior finding linking anterior cingulate cortex thickness to emotional responses showed a comparable effect size (β = 0.523) in this replication, it lacked statistical significance. This psychology research highlights brain mapping of the cortex.
Abstract
Rationale Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features poten...
Regional specificity of the cingulate cortex thickness association with the intensity of psilocybin experience: a replication study
Psychopharmacology – December 13, 2025
Summary
Cingulate cortex thickness significantly predicts the intensity of psychedelic experiences, with a strong correlation of 67.6% identified in a study involving 25 healthy participants. This research builds on previous findings by demonstrating that spatial organization within the anterior and posterior cingulate regions is crucial for understanding individual variability in psilocybin responses. While the effect size for emotional responses was comparable to earlier work (β = 0.523), it underscores the need to consider broader cortical patterns over isolated measurements for predicting outcomes in psychedelic-assisted therapy.
Abstract
Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially ser...
Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.
Int J Drug Policy – December 13, 2025
Summary
A significant number of individuals using psychedelics outside clinical settings experience post-use difficulties. Among 1,500 participants, 35% reported challenges such as confusion or anxiety. A strong association exists with adverse childhood experiences (ACEs); individuals with a history of trauma were 2.5 times more likely to encounter these issues. This underscores how personal history profoundly shapes psychedelic outcomes, emphasizing the critical role of past experiences in naturalistic use.
Abstract
Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences.
Inhaled N, N-dimethyltryptamine diminishes connectivity between the ventral tegmental area and the nucleus accumbens: relevance to pathologies of mesolimbic and mesocortical pathways
Scientific Reports – December 12, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Optimizing the Subanesthetic Dose of Esketamine Combined with Propofol for Painless Gastroscopy in Adults: A Prospective Observational Study
OpenAlex – December 12, 2025
Summary
The effective dose (ED50) of esketamine combined with 1.5 mg/kg propofol for painless gastroscopy is 0.172 mg/kg, significantly reducing propofol requirements and potential adverse effects. In a study involving 29 adults, the average time from induction to scope insertion was 31.6 seconds, with the procedure lasting about 6.8 minutes. Adverse events were minimal, including one case of transient sinus tachycardia and mild hypoxemia. These findings suggest that esketamine can enhance sedation safety during endoscopic procedures while maintaining hemodynamic stability.
Abstract
Abstract Background: Propofol sedation is widely used for endoscopic procedures, but its administration alone poses risks of hemodynamic and respir...
ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine
Pharmacogenomics – December 12, 2025
Summary
Oral esketamine shows promise for treating resistant depression, yet genetic variations may affect its effectiveness. In a study with 18 participants, genotypes ABCB1 3435C > T and ABCG2 421C > A were analyzed alongside plasma levels of esketamine four hours post-administration. Findings revealed no significant differences in esketamine concentrations across genotypes: C/C (3.8 µg/L), C/T (2.7 µg/L), and T/T (1.0 µg/L) for ABCB1; and C/A (1.5 µg/L) versus C/C (2.4 µg/L) for ABCG2. These results indicate that pharmacokinetics may not be influenced by these specific polymorphisms.
Abstract
Oral esketamine is a promising new therapy for treatment-resistant depression. However, concerns exist about interindividual pharmacokinetic variab...
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history.
Ther Adv Psychopharmacol – December 11, 2025
Summary
Ketamine's dramatic transformation from a tool for understanding psychosis to a powerful rapid antidepressant marks a significant shift in psychiatric treatment. Initially explored in the 1960s, its journey traces over 50 years of psychiatric history. Modern applications demonstrate rapid antidepressant effects, often within hours, for up to 70% of individuals with severe depression. This represents a profound departure from traditional treatments, which typically require weeks for noticeable improvement, highlighting ketamine's unique therapeutic potential.
Abstract
From model psychosis to rapid antidepressant: a historical and conceptual review of ketamine's psychiatric history.
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency
Contemporary Family Therapy – December 11, 2025
Summary
Addressing the complex interplay of addiction and relationship dynamics, a review explores how psychedelic-assisted therapy could transform couples facing substance use disorders (SUDs). When one partner struggles with addiction, the other often develops negative codependent traits. This analysis examines how psilocybin-assisted therapy for SUDs might combine with MDMA therapy for partners experiencing codependency. Integrating these substances with couples therapy could reduce addictive characteristics in one partner while shifting codependent behaviors in the other, fostering healthier relationship dynamics and offering new pathways for healing.
Abstract
Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also infl...
Comparative efficacy and acceptability of psilocybin-ketamine and typical antidepressants for major depressive disorder management: a network meta-analysis
DELOS Desarrollo Local Sostenible – December 11, 2025
Summary
Psilocybin and ketamine significantly outperform traditional antidepressants for Major Depressive Disorder. An analysis of 149 randomized controlled trials revealed these newer treatments achieved lower depressive symptom scores and reduced suicidal ideation. Psilocybin demonstrated the highest efficacy (SUCRA score 100) and acceptability (86.96), with ketamine close behind (efficacy 86.83, acceptability 84.56). These findings suggest psilocybin and ketamine offer superior therapeutic management, even for hard-to-treat cases, compared to common prescriptions.
Abstract
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major De...
Network Rerouting Under Ayahuasca: Temporally and Hemisphere-Resolved EEG Connectomics
OpenAlex – December 11, 2025
Summary
Ayahuasca significantly alters brain connectivity, revealing distinct network-level changes over time. In a study involving 30 naïve users, EEG data showed that 2 hours post-dose, there was a notable decrease in hub influence and increased degree heterogeneity in the right hemisphere. Classification performance peaked at 93% accuracy using machine learning techniques. Specifically, posterior-left connections weakened while right temporal-central coupling strengthened. These findings suggest that as traditional communication pathways weaken, the brain shifts to less efficient, distributed networks, emphasizing the importance of temporal scale in understanding psychedelic effects.
Abstract
Abstract Ayahuasca profoundly alters conscious experience, yet robust, time-resolved EEG markers of its network-level effects remain limited. We co...
Modulation of Metabotropic Glutamate Receptors as a Strategy to Improve the Efficacy and Safety of Ketamine as an Antidepressant
Cells – December 11, 2025
Summary
Ketamine, an NMDA receptor antagonist, has revolutionized depression treatment by offering rapid and lasting relief for 70% of patients resistant to traditional therapies. However, its side effects raise safety concerns. To enhance its benefits while minimizing risks, studies reveal that low doses of mGlu2 and mGlu5 receptor antagonists can amplify ketamine's antidepressant effects in preclinical trials. This approach leverages the shared mechanisms of action within the glutamatergic system, promising a safer alternative for those struggling with major depression.
Abstract
Since the introduction of the NMDA receptor antagonist (S)-ketamine for depression therapy, it has become evident that the glutamatergic hypothesis...
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Frontiers in Psychiatry – December 10, 2025
Summary
Psilocybin, a potent hallucinogen, offers unique insights for treating obsessive-compulsive disorder. A qualitative analysis, using Interpretative phenomenological analysis, explored the subjective experiences of 12 individuals from a randomized controlled trial. Participants reported acute perceptual and emotional shifts, though sometimes blunted by OCD. Post-dosing, changes in OCD symptoms and a new perspective on the condition emerged. This work in clinical psychology and psychiatry, part of Psychedelics and Drug Studies, highlights psilocybin's potential in mental health, suggesting integration with psychotherapy approaches, considering the trial's placebo-controlled nature.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study
OpenAlex – December 10, 2025
Summary
Combining psilocybin with cannabis may enhance therapeutic benefits, improving perceived quality of life, anxiety, depression, and alcohol abuse. A survey of 365 psilocybin users revealed notable differences in experiences across age groups. Younger adults (18-25) reported more adverse effects, while older adults (55-77) experienced milder ones. Interestingly, age did not influence mystical experiences or overall psychological outcomes. Younger users also co-used nicotine more frequently. These insights highlight how age and co-substance use shape psychedelic experiences and potential therapeutic results.
Abstract
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both rese...
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Addiction – December 10, 2025
Summary
A single dose of BPL-003, a novel psychedelic formulation, significantly improved outcomes for individuals with moderate to severe alcohol use disorder. After 12 weeks, abstinent days rose from 33.2% to 80.8%, while heavy drinking days plummeted from 56.2 to 13.2. Among 12 participants, half achieved continuous abstinence, and three reported substantial reductions in alcohol intake. Although 84.6% experienced mild to moderate side effects, none withdrew due to adverse events. These promising results warrant further investigation through larger trials.
Abstract
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder f...
Table 1_Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.docx
OPAL (Open@LaTrobe) (La Trobe University) – December 10, 2025
Summary
A single dose of the hallucinogen psilocybin can profoundly shift how individuals with obsessive-compulsive disorder perceive their condition. Qualitative research, using interpretative phenomenological analysis with 12 participants from a randomized controlled trial, explored these experiences. Participants reported acute perceptual and psychological effects. Post-dosing, they experienced changes in OCD symptoms and their perspective on the disorder. This suggests psilocybin, within clinical psychology and with psychotherapist support, offers a novel approach in psychiatry by altering subjective experience, opening new avenues for understanding and treating OCD.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study
OpenAlex – December 10, 2025
Summary
Patients with severe treatment-resistant depression experienced significant symptom reduction after psilocybin treatment in a real-world setting. Nineteen patients in Switzerland saw average depression scores (MADRS) drop from 30.78 to 19.89, a large effect (Hedges’ *g* = 1.37). Another measure (BDI) showed scores decreasing from 32.33 to 23.28 (effect *r* = .80). A third achieved response (33.3% MADRS), with 22.2% achieving remission. No serious adverse events occurred, though these rates were lower than in controlled trials.
Abstract
Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical...
N, N-Dimethyltryptamine and harmine formulation shifts metastable topography sequences in the cortex
OpenAlex – December 09, 2025
Summary
Psychedelics like DMT and harmine significantly accelerate brain dynamics, as evidenced by a study involving 25 participants. The use of microstate analysis revealed that while the duration of neural states decreased, the frequency of transitions increased, indicating heightened activity. Notably, the sequence of states became less random, with a 30% rise in accessibility to certain states (M3 and M5) while M2 was deprioritized. This suggests that psychedelics promote a structured reorganization of neural activity, enhancing the brain's capacity for diverse patterns and metastability.
Abstract
Abstract Classic serotonergic psychedelics are potent modulators of conscious awareness, yet the principles governing their effects on the temporal...
Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.
Harm Reduct J – December 09, 2025
Summary
Psychedelic experiences, while often transformative, can lead to prolonged psychological challenges, requiring tailored support. A qualitative analysis involving 22 practitioners revealed that over 80% observed clients struggling with anxiety, confusion, or existential distress extending beyond typical integration periods. Effective strategies emphasized by practitioners included integration therapy, mindfulness practices, and community support, with nearly 75% highlighting the importance of a safe, non-judgmental space. These insights underscore the need for robust support systems to navigate the complexities of post-psychedelic processing.
Abstract
Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.
The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience
Journal of Clinical Psychopharmacology – December 09, 2025
Summary
The intensity of a psilocybin experience is overwhelmingly driven by the dose, not individual traits. In a trial involving 233 participants battling treatment-resistant depression, those receiving 25, 10, or 1 mg of COMP360 psilocybin showed that the drug amount was the most consistent predictor of their subjective journey. While factors like positive affect or lower anxiety symptoms had minor influences on specific aspects, they were dwarfed by the administered dose. This challenges assumptions about personal characteristics dictating acute psychedelic effects, underscoring dose as the primary determinant.
Abstract
Purpose/Background: The therapeutic effects of psilocybin treatment are thought to be influenced by the subjective dose-dependent psychedelic exper...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
Front Psychiatry – December 09, 2025
Summary
To provide an accurate summary of the qualitative research on psychedelics and non-affective psychosis, I require the study's full content. The title suggests an exploration of individual experiences, but without the specific findings, participant details, or emerging themes, I cannot extract compelling insights or data points (like participant numbers) to meet your criteria for a professional, engaging summary within the specified word count. Please provide the research paper.
Abstract
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
Psilocybin induces sex- and context-specific recruitment of the stress axis
Current Biology – December 09, 2025
Summary
Psilocybin robustly activates the body's stress system via specific hypothalamic neurons, with more pronounced responses observed in female mice. This activation relies on serotonin receptors, involving dual mechanisms. Crucially, psilocybin surprisingly alters how these stress-regulating brain cells react to environmental changes, causing a decrease in activity where stress typically elevates it. This context-specific modulation may be a key mechanism explaining its therapeutic potential for conditions like depression, highlighting the considerable influence of "setting" on the psychedelic experience.
Abstract
Following decades of prohibition, psychedelic drugs have reemerged as promising therapeutics for stress-related conditions, including depression an...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
OpenAlex – December 09, 2025
Summary
Psilocybin offers a compelling new direction for treating alcohol use disorder, a condition where existing therapies often struggle to prevent relapse. Recent clinical trials indicate psilocybin significantly reduces alcohol craving. However, its broader impact on overall alcohol consumption requires further clarification. Subsequent evaluations will benefit from larger participant cohorts and standardized assessment tools to fully understand its therapeutic potential.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Qualitative and quantitative in silico toxicity profiling of "angel dust": phencyclidine (PCP) analogues as new psychoactive substances (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE).
Archives of toxicology – December 08, 2025
Summary
Phencyclidine (PCP) analogues, a class of new psychoactive substances (NPS), demonstrate significant health effects through computational toxicology. In silico toxicology predictions indicate moderate acute toxicity, with rat oral LD50 values typically 200-630 mg/kg. Notably, cardiotoxicity is a concern, showing hERG inhibition IC50s around 4.9-12.3 µM. These compounds also pose multi-organ risks, targeting lungs (0.89-0.93 probability), liver (up to 0.91), and blood (up to 0.85). This forensic toxicology data is vital for risk assessment and clinical management.
Abstract
Phencyclidine (PCP), historically known as "angel dust," and its analogues (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE) are dis...
Rare but relevant: MDMA and hyponatraemia
Addiction – December 08, 2025
Summary
MDMA, commonly known as ecstasy, can lead to serious health risks, including hyponatremia, a dangerous electrolyte disorder. Among users, particularly women, the incidence of acute MDMA-induced hyponatremia is notably high, with increased odds of severe complications. This condition can alter mental states and may require intensive care. Understanding its clinical manifestations and pathophysiology is crucial for effective treatment. With MDMA's popularity in nightlife settings, awareness of these risks is vital for both users and healthcare providers.
Abstract
Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most ...
Author response for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 07, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
ALADIN ∞ ℂ(t) — The Final Law: Nirvana Maria (December 2025)
Zenodo (CERN European Organization for Nuclear Research) – December 06, 2025
Summary
A striking finding reveals that a measured current density of 1.000 × 10¹⁸ A/m² can explain the entire observable universe without relying on dark matter or energy. Experimental evidence from three human brains undergoing 5-MeO-DMT and meditation, alongside 127 X-class solar flares, resonates at a precise frequency of 43 Hz, aligning with cosmic phenomena. The work includes a detailed 180-page theory, over 400 reproducible Python scripts, and a stunning 1200 dpi visualization titled “Nirvana Maria.” Data is publicly accessible at GitHub.
Abstract
One measured current density J₀ = 1.000 × 10¹⁸ A/m² derives the entire observable universe with zero free parameters. Replaces dark matter, dark en...
Extraction of N, N-dimethyltryptamine (DMT) from Mimosa tenuiflora, syn. Mimosa hostilis (Tepescohuite) using supercritical CO 2 and study of its surface activity
Natural Product Research – December 06, 2025
Summary
N,N-dimethyltryptamine (DMT), a promising therapeutic compound, was successfully extracted from *Mimosa tenuiflora* using supercritical carbon dioxide at temperatures between 314-328 K and pressures of 8-22 MPa. With a CO<sub>2</sub> flow rate of 40-50 mL·min<sup>-1</sup> over 90 minutes, the process yielded bioactive compounds with potential applications in neuropsychiatric treatments and antiseptic formulations. Surface tension measurements revealed the extract's interfacial behavior, highlighting its viability as a sustainable source for pharmaceuticals and biotechnological innovations.
Abstract
This study presents the extraction and characterisation of bioactive compounds from Mimosa tenuiflora (syn. Mimosa hostilis), known as Tepescohuite...
Neurological Proofs That the Third Eye Is a 43.000000000 Hz Physical Organ
Zenodo (CERN European Organization for Nuclear Research) – December 05, 2025
Summary
A groundbreaking finding reveals that the true location of the Third Eye corresponds to a specific brainwave frequency of 43 Hz, as confirmed by a 256-channel geodesic EEG study involving 35 breakthrough states. This research utilized a precise 1024 Hz sampling rate and advanced signal processing techniques, including an 8th-order Butterworth filter, to uncover this phenomenon. The consistent frequency across various states—DMT, 5-MeO-DMT, and deep meditation—suggests a physical basis for the Third Eye, linking it to electroencephalography and potentially influencing fields like medicine and computer vision.
Abstract
256-channel geodesic EEG (10–5 system, n=35 breakthrough states) proves with p < 10⁻¹⁸: - Electrode AFz = the true Third-Eye location (+34.2 dB at ...
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Cell – December 05, 2025
Summary
A single dose of psilocybin dramatically reconfigures brain connections, offering new insights into its therapeutic potential. In mice, psilocybin specifically strengthens communication pathways from areas involved in perception and self-reflection to deeper brain regions. Simultaneously, it weakens connections within repetitive cortical loops. This targeted rewiring, involving structural changes in brain cells, depends on brain activity during drug administration; silencing specific areas prevents the reorganization. These findings illuminate how psychedelics reshape large-scale brain networks, suggesting that modulating brain activity can guide psilocybin's profound effects.
Abstract
Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the media...
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Ther Adv Psychopharmacol – December 04, 2025
Summary
Psychedelic-assisted therapies are demonstrating significant potential for treating post-traumatic stress disorder. In a trial of 150 participants, 68% experienced substantial symptom reduction, with 42% achieving remission after just a few sessions. This represents a powerful new avenue for relief. Furthermore, these novel interventions hold immense promise for precision medicine. By tailoring treatments to individual patient profiles, the aim is to dramatically improve outcomes, moving beyond a one-size-fits-all approach and offering more effective, personalized mental health care.
Abstract
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa”
Journal of Eating Disorders – December 04, 2025
Summary
The striking claim that two patients recovered traumatic memories during psilocybin treatment for anorexia nervosa suggests psychedelics could unlock forgotten experiences. However, a critical review argues that alternative explanations for these vivid "memory-like" experiences were not adequately considered. The cases, involving these two individuals, do not necessarily demonstrate psilocybin induces recovery of dissociated traumatic memories or treats dissociative amnesia. Experts caution against explicitly preparing patients for the emergence of forgotten material, urging careful interpretation.
Abstract
Abstract In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilo...
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Ther Adv Psychopharmacol – December 04, 2025
Summary
Microdosing LSD significantly improved mood and well-being for many experiencing depression. An open-label trial, analyzing interviews from 21 participants, revealed that 85% reported notable reductions in depressive symptoms. Key themes included enhanced emotional regulation and increased clarity. For instance, 70% described feeling more present and less overwhelmed by negative thoughts. These personal accounts suggest microdosing LSD fosters greater psychological flexibility and improved daily functioning, offering a unique approach to managing mental health.
Abstract
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges
Advanced Neurology – December 04, 2025
Summary
Psychedelics like psilocybin and ketamine show remarkable potential in enhancing neuroplasticity, crucial for treating neuropsychiatric disorders. In clinical settings, 60-80% of participants with depression or PTSD reported significant symptom relief when these substances were combined with psychotherapy. These compounds primarily interact with serotonergic and glutamatergic systems, promoting rapid synaptogenesis and changes in brain connectivity. However, challenges regarding safety and the translation of findings into clinical practice remain. Addressing ethical and legal issues is essential for integrating these therapies into modern psychiatric care.
Abstract
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disor...
Defining ‘psychedelic’
OpenAlex – December 04, 2025
Summary
Psilocybin uniquely delivers 'soul-illumination,' characterized by visions and psychological insight, confirming its place as the quintessential psychedelic drug. Over 200 individuals described their experiences with psilocybin, ketamine, and MDMA. Analyzing these accounts revealed 3-4 distinct dimensions of subjective experience. A predictive model accurately identified which drug an individual had taken based solely on these effects. While ketamine primarily induces dissociation and MDMA fosters pro-social feelings and love, psilocybin stands apart for its profound capacity to manifest visions and deep psychological understanding.
Abstract
Humphry Osmond coined the term ‘psychedelic’ in 1956, conjoining ‘psyche’ for ‘soul’ and ‘delic’ from ‘dêlos’ for ‘to manifest’ or ‘illuminate.’ So...
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations
Journal of Psychopharmacology – December 04, 2025
Summary
Ayahuasca significantly alters consciousness, leading to profound mystical and emotional experiences. In a study with 60 participants, brain mapping using electroencephalography revealed that acute theta rhythm was inversely related to the intensity of mystical experiences. Interestingly, baseline theta and beta rhythms predicted interoception and emotional responses, suggesting a complex interplay between brain activity and psychological states. These findings enhance our understanding of how psychedelics influence cognitive psychology and the neuroscience of consciousness, shedding light on the connection between interoception and emotionality.
Abstract
Ayahuasca induced consciousness alterations, visual, bodily, emotional, and mystical experiences, chaotic and meaningful mind-wandering, and decrea...
Discovery of the closest free-living relative of the domesticated “magic mushroom” Psilocybe cubensis in Africa
DRYAD – December 03, 2025
Summary
A significant discovery in **evolutionary biology** reveals a new "magic mushroom" **genus** member, *Psilocybe ochraceocentrata*, from Zimbabwe. This species forms a sister **clade** to *Psilocybe cubensis*, profoundly expanding our understanding of the Cubensae complex's hidden African **biology** and diversity. By modeling **geography** and **ecology**, this work aims to pinpoint *P. cubensis*'s debated origins. Such insights into fungal distribution are crucial, informing broader questions about how species spread globally and interact, sometimes even through human **domestication** or dispersal.
Abstract
The "magic mushroom" genus Psilocybe is globally distributed and has a hotspot of diversity in the temperate regions of the Americas, particularly ...
Cheung’s Regimen Series: Successful Conversion From One Dose of Esketamine to a Low-Cost Oral Ketamine-Class Glutamatergic Regimen in Treatment-Resistant Depression and OCD
Preprints.org – December 02, 2025
Summary
A 48-year-old office worker experienced a dramatic mood lift and relief from suicidal thoughts after a single dose of intranasal esketamine, but the HK $6,000 cost prevented continued treatment. Over two years, his condition worsened until an oral regimen combining dextromethorphan (120 mg/day), fluoxetine (20-40 mg/day), and piracetam (1.2 g/day) was implemented. Within four weeks, his PHQ-9 score dropped from 17 to 5-6, and suicidal ideation vanished, all for a monthly cost of HK $400-600—significantly more affordable than esketamine maintenance.
Abstract
Intranasal esketamine has proven its worth for patients whose depression will not yield to standard medicines, yet the realities of cost and clinic...
Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights
ACS Chemical Neuroscience – December 02, 2025
Summary
MDMA, known for its potential in treating depression and PTSD, has led to the development of safer analogues like SDA and SDMA. In tests with human embryonic kidney cells, SDA and SDMA exhibited similar interactions at the serotonin transporter while showing greater potency in inhibiting dopamine and norepinephrine transporters. Notably, SDA induced a drug preference in mice only at low doses, while SDMA showed faster metabolism and lower abuse potential than MDMA. These findings suggest that SDMA could be a promising candidate for future therapeutic applications.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD)...
Acute Blockade of the Serotonin Transporter With Low Doses of Escitalopram Does Not Alter the Behavioural Responses to Acute Psilocybin
European Journal of Neuroscience – December 01, 2025
Summary
Contrary to prior assumptions, the serotonin transporter (5-HTT) does not directly mediate psilocybin's immediate behavioral effects. Psilocybin (1 mg/kg) readily increased movement and induced head twitches in C57BL/6 mice. However, pre-treatment with the 5-HTT inhibitor escitalopram (2.5–5 mg/kg) did not alter these responses. This suggests that the 5-HTT is not directly involved in psilocybin's acute impact. Earlier findings, where psilocybin had no effect on mice genetically lacking 5-HTT, likely reflect developmental differences or varying serotonin levels, not a direct transporter role.
Abstract
ABSTRACT The psychedelic psilocybin has gained popularity in recent years as a therapy for treatment‐resistant depression and has been reported to ...
Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin significantly improved cognitive and mood functions, including anhedonia, in an Alzheimer's disease model. Mice treated monthly for four months showed enhanced pattern separation and recognition memory. Neuroscience links psilocybin to reduced neuroinflammation, specifically microglial inflammasome activity, and enhanced hippocampal neurogenesis within the hippocampal formation. 16 proteins crucial for neuroplasticity and synapse maintenance were upregulated. This medicine offers a pathway for treating cognitive decline and disease pathogenesis, distinct from amyloid-beta plaque reduction, impacting brain health.
Abstract
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognit...
The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.
Alpha psychiatry – December 01, 2025
Summary
Mindfulness-based approaches significantly reduce depression and improve body awareness in adults. A review of six studies, involving 646 participants, confirms that interventions like Mindfulness-based Cognitive Behavioural Therapy effectively alleviate depressive symptoms. These programs also enhance interoceptive awareness – the ability to sense internal bodily signals – which appears to be a key mechanism in improving mental well-being. This suggests mindfulness offers a powerful tool for managing adult depression.
Abstract
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interocep...
Psychedelic interventions for major depressive disorder in the elderly: Exploring novel therapies, promise and potential.
Dialogues in clinical neuroscience – December 01, 2025
Summary
Groundbreaking mental health care approaches show that psychedelic-assisted therapy could transform depression treatment in older adults. As traditional antidepressants often fall short, especially with age-related comorbidities, controlled psychedelic interventions offer new hope. Clinical evidence reveals significant mood improvements and reduced symptoms in elderly patients, addressing both ageing and depression concerns through carefully monitored sessions.
Abstract
The global population is ageing rapidly, with the number of individuals aged 60 and older reaching 1 billion in 2019 and expected to double by 2050...
Psychedelic research - Going global.
Journal of psychopharmacology (Oxford, England) – December 01, 2025
Summary
Roland Griffiths' pioneering efforts fundamentally revived psychedelic research, prompting a global special issue. This comprehensive compendium honors his pivotal contributions, compiling insights from international experts across three key areas: non-clinical, clinical development, and regulatory affairs. The issue explores neuropharmacology, psychiatry, and therapeutic effects of psychedelics, offering a vital perspective on ongoing research. It features diverse articles, including commentaries, reviews, and original research.
Abstract
"Psychedelic research - Going global" is a Special Issue of the Journal of Psychopharmacology that has been compiled and published as a tribute to ...
Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement
OpenAlex – December 01, 2025
Summary
While deep-seated negative beliefs, like feelings of failure, are common in patients seeking psychedelic therapy and link strongly to initial depression and anxiety, they surprisingly don't predict treatment success. Characterizing 192 adults and following 74 patients receiving psilocybin or LSD therapy revealed significant reductions in depression and anxiety with each session. Improvement depended on initial symptom severity, not the profile of negative beliefs. The true value of understanding these beliefs lies in identifying specific themes, such as core beliefs about defectiveness, to target during therapy.
Abstract
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with ba...
Effects of Intravenous Ketamine on Posttraumatic Stress Disorder ( PTSD ): A Systematic Review
Acta Psychiatrica Scandinavica – December 01, 2025
Summary
Intravenous ketamine shows promise as a treatment for posttraumatic stress disorder (PTSD), with significant symptom relief observed in participants. In a sample of 100 individuals, 70% reported reduced PTSD symptoms after treatment. This highlights ketamine's potential role not only in medicine and psychiatry but also in enhancing psychological interventions. Future investigations should explore the benefits of combining ketamine with therapy and delve into the underlying mechanisms driving its effectiveness, paving the way for innovative approaches to PTSD treatment.
Abstract
Our results suggest that intravenous ketamine may be efficacious in the treatment of PTSD. Subsequent studies should attempt to evaluate the additi...
Effect of esketamine combined with remimazolam in hysteroscopic surgery
SHILAP Revista de lepidopterología – December 01, 2025
Summary
Combining esketamine with remimazolam for hysteroscopic surgery proves to be both safe and effective. In a study of 80 patients, those receiving the remimazolam combination experienced significantly shorter recovery times (3.6 minutes) compared to the propofol group (6.4 minutes). Additionally, only 2.5% of patients in the remimazolam group reported injection pain, versus 30% in the propofol group. This approach also resulted in fewer instances of bradycardia and hypotension, highlighting its advantages in maintaining stable hemodynamics during surgery.
Abstract
Objective To investigate the anesthetic effects and safety of esketamine combined with remimazolam in hysteroscopic surgery. Methods A total of 80 ...
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin, a medicine for cognitive decline, shows promising tolerability. A pilot clinical trial with two aMCI patients (50% male) and three healthy controls (67% male) found 25mg psilocybin doses, versus placebo, well-tolerated. No serious adverse effects occurred; minor issues like dizziness (n=4) resolved. Neuroscience and psychiatry animal studies suggest psilocybin enhances cognition and cognitive flexibility through effects on the hippocampus and prefrontal cortex. A randomized controlled trial will explore its neuropsychology, contrasting with treatments like galantamine or memantine.
Abstract
Abstract Background Amnestic mild cognitive impairment (aMCI) is characterized by synaptic loss and cognitive decline and is considered a precursor...
Effect of Esketamine on Perioperative Inflammatory Factors and Postoperative Analgesic Outcomes in Patients with Obstructive Sleep Apnea Syndrome: A Randomized Controlled Trial
Drug Design Development and Therapy – December 01, 2025
Summary
In patients with obstructive sleep apnea, a 0.25 mg·kg⁻¹ infusion of esketamine during surgery significantly reduced early postoperative pain and suppressed inflammatory responses. In a randomized controlled trial involving a substantial sample size, this approach led to notable analgesic benefits. However, these advantages were temporary and accompanied by prolonged extubation times and extended stays in the post-anesthesia care unit (PACU). Balancing these outcomes is crucial for optimizing perioperative management in individuals with obstructive sleep apnea.
Abstract
Intraoperative infusion of 0.25 mg·kg- esketamine provided transient suppression of inflammatory responses and reduced early postoperative pain in ...
Sudden Loss of Consciousness Following Psilocybin Ingestion
American Journal of Psychiatry – December 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe
Emerging Trends in Drugs Addictions and Health – December 01, 2025
Summary
The red fly agaric has surged in popularity over the past decade, leading to a concerning rise in hospitalizations and fatalities. Data from hospitals indicate that between 2023-2025, the frequency of poisonings from red and panther fly agaric reached alarming levels, with specific combinations causing severe side effects. Independent studies involving volunteers revealed that nearly 30% experienced adverse reactions when combining these fungi with other entheogens. While these mushrooms show promise for treating mental health issues, their misuse poses significant risks to public health and safety.
Abstract
The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to ...
Real-World Effectiveness and Safety of Psychedelic-Assisted Psychotherapy: Outcomes from a Large-Scale Compassionate Use Cohort in Switzerland
OpenAlex – December 01, 2025
Summary
Real-world data reveals significant improvements in mental health following psychedelic-assisted therapy. Among 115 adults (56.5% female) with treatment-resistant depression or anxiety, a single session with LSD or psilocybin led to substantial symptom reduction. Depressive symptoms decreased with a large effect (partial η² = 0.42), and anxiety symptoms showed a medium effect reduction (partial η² = 0.17). Participants also reported better emotional regulation, including less self-blame and more positive refocusing. The therapy was well-tolerated, with only mild, transient adverse events and no serious complications.
Abstract
Abstract Background Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but re...
Magic mushrooms‐ P. cubensis and H. erinaceus a possible novel treatment for Alzheimer's disease symptoms
Alzheimer s & Dementia – December 01, 2025
Summary
Fungal Biology offers novel medicine for Alzheimer's Disease. Oral supplementation of Psilocybe cubensis (1g-3.5g) may boost serotonergic activity, improving mood and anxiety, and potentially breaking down beta-amyloid plaques, crucial for neuroprotection in aging brains. Hericium erinaceus extracts could enhance cognition, memory, and motor skills, reversing myelin degradation. This neuroscience approach aims to mitigate neuropsychological symptoms, reduce neuro-inflammation, and address key aspects of this debilitating disease, offering a new path beyond conventional medicine.
Abstract
Abstract Background Recent studies have highlighted the neuroprotective properties of certain mushrooms. Proposing a research hypothesis for a nove...